Benefits and limitations of current antiplatelet therapies

American Journal of Health-System Pharmacy

Volumn 65, Issue 13 SUPPL. 5, 2008, Pages

  Nappi, Jean ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute coronary syndrome; Aspirin; Combined therapy; Mechanism of action; Mortality; Platelet aggregation inhibitors; Protocols; Thienopyridines

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; STREPTOKINASE; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; AWARENESS; BLEEDING; CONFERENCE PAPER; CORONARY STENT; DRUG ELUTING STENT; DRUG WITHDRAWAL; GENETIC ANALYSIS; HEALTH CARE PERSONNEL; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT FAILURE; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

EID: 46149085660     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080156     Document Type: Conference Paper

References (29)

1. Rezkalla SH, Benz M. Antiplatelet therapy from clinical trials to clinical practice Clin Med Res. 2003;1:101-4.
2. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41:961-5.
3. Smith SC Jr, Allen J, Blair SN et al; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113:2363-72.
4. Behan MWH, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J. 2004; 80:155-64.
5. Lewis HD Jr, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983; 309:396-403.
6. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 332:349-60.
7. Martin CP, Talbert RL. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy. 2005; 25:942-53.
8. Lee P-Y, Chen W-H, Ng W et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005; 118:723-7.
9. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993; 71:397-403.
10. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ. 2004; 328:477-9.
11. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006; 367:606-17.
12. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502.
13. Sabatine MS, Morrow DA, Montalescot G et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005; 112:3846-54.
14. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005; 366:1607-21.
15. Mehta SR, Yusuf S, Peters RJG et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358:527-33.
16. Grines CL, Bonow RO, Casey DE Jr. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Intervention, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007; 115:813-8.
17. Schömig A, Neumann F-J, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084-9.
18. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med. 1998; 339:1665-71.
19. Steinhubl SR, Berger PB, Mann III JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA. 2002; 288:2411-20.
20. van der Hoeven BL, Pires NM, Warda HM et al. Drug-eluting stents: results, promises and problems. Int J Cardiol. 2005; 99:9-17.
21. Farb A, Boam AB. Stent thrombosus redux - The FDA perspective. N Engl J Med. 2007; 356:984-7.
22. Steinhubl SR, Berger PB, Brennan DM et al. Optimal timing for the initiation of pre-treatment with 300 mg Clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol. 2006; 47:939-43.
23. Chan AW, Moliterno DJ, Berger PB et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J. Am Coll Cardiol. 2003; 42:1188-95.
24. Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pre-treatment with clopidogrel. N Engl J Med. 2004; 350:232-8.
25. Mehilli J, Kastrati A, Schuhlen H et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004; 110:3627-35.
26. Patti G, Colona G, Pasceri V et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients underoging coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) Study. Circulation. 2005;111:2099-106.
27. Lev EI, Patel RT, Maresh KJ et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J Am Coll Cardiol. 2006;47:27-33.
28. Hulot J-S, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108:2244-7.
29. Riddell JW, Chiche L, Plaud B et al. Coronary stents and noncardiac surgery. Circulation. 2007; 116:e378-82.